A phase i study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2726-2731

  Albanell, Joan ^a,d   Montagut, Clara ^a   Jones, Eileent ^b   Pronk, Linda ^c   Mellado, Begoña ^a   Beech, Janette ^b   Gascon, Pere ^a   Zugmaier, Gerhard ^c   Brewster, Michael ^c   Saunders, Mark P ^b   Valle, Juan W ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CHILD; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; LUNG EMBOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; MIDDLE AGED; NEOPLASM;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 52049104951     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1980     Document Type: Article

References (43)

1. Sundaresan S, Penuel E, Sliwkowski MX. The biology of human epidermal growth factor receptor 2. Curr Oncol Rep 1999;1:16-22.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2: 127-37.
3. Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to mul-
4. tiple stromal ligands. Biochim Biophys Acta 1998; 1377: M 25-37.
5. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
6. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999;447:227-31.
7. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-28.
8. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37.
9. Sliwkowski MX, Schaefer G, Akita RW, et al. Coex-pression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269:14661-5.
10. Schaefer G, FitzpatrickVD, Sliwkowski MX. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175. Oncogene 1997;15:1385-94.
11. Fitzpatrick VD, Pisacane Pl,Vandlen RL, et al. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett1998;431:102-6.
12. Liu J, Kern JA. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am J Respir Cell Mol Biol 2002;27:306-13.
13. Mendoza N, Phillips GL, Silva J, et al. Inhibition of ligand-mediated HER2 activation in androgen-inde-pendent prostate cancer. Cancer Res 2002;62: 5485-8.
14. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60.
15. Fendly BM,Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50: 1550-8.
16. Lewis GD, Lofgren JA, McMurtrey AE, et al. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 1996;56:1457-65.
17. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergisti-cally inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6.
18. Malik MA, Totpal K, Baiter I, et al. Dose-response studies of recombinant humanised monoclonal antibody 2C4 in tumour xenograft models [abstract]. Proc Am Assoc Cancer Res 2003:44:773.
19. FriessT, Bauer S, Burger AM, et al. In vivo activity of recombinant humanised monoclonal antibody 2C4 in xenografts is independent of tumour type and degree of HER-2 overexpression [abstract]. EORTC-NCI-AACR Conference, Frankfurt, Germany 2002:953.
20. Mann M, Sheng H, Shao J, et al. Targeting cycloox-ygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001:120: 1713-9.
21. Agus DB, Gordon MS,Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43.
22. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. EurJ Cancer1998;34:1274 - 81.
23. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998:16:1795-802.
24. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291 -7.
25. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90:1190-7.
26. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.
27. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91.
28. Delord JP, Pierga JY, DierasV, et al. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer 2005;92:820-6.
29. O'Shaughnessy J, Miles D,Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23.
30. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refracto-ry metastatic breast cancer. J Clin Oncol 1999;17: 485-93.
31. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000;18:1337-45.
32. Bruno R, Washington CB, Lu JF, et al. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005:56:361 -9.
33. Ng CM, Lum BL, Gimenez V, et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006;23:1275-84.
34. HolbroT, Civenni G, Hynes NE.The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
35. Chen X, YeungTK, Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 2000;277: 757-63.
36. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40:85-104.
37. Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 2006;94:964-8.
38. Cortes J, Baselga P, Kellokumpu-Lehtinen G, et al. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2 [abstract]. J Clin Oncol 2005;23:208.
39. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhu MAb 2C4 C), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-32.
40. Bossenmaier B, Hasmann M, Koll H. Presence of HER2/HER3 heterodimers predicts antitumor effects of pertuzumab (OMNITARG) in different human xenograft models [abstract 5342]. Proc Am Assoc Cancer Res 2004:45:1232.
41. Johnson BE, Janne PA. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res 2006;12:4436-40s.
42. Walshe JM, Denduluri N, Berman AW, et al. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer 2006;6: 535-9.
43. Baselga J, Cameron D, Miles D, et al. Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T [abstract 1004], J Clin Oncol 2007;25.